New Drug Daraxonrasib Doubles Pancreatic Cancer Survival in Landmark Trial

Pancreatic cancer remains one of medicine's most stubborn killers, with a five-year survival rate stuck at 13% even as overall cancer survival has improved dramatically. The core problem has long been the KRAS gene mutation, present in the vast majority of pancreatic cancers and a major driver across many cancer types. For decades, KRAS was labeled 'undruggable' because its protein structure offered no obvious site for a drug to bind and block it.

That changed when researchers identified a hidden pocket on the KRAS G12C variant, enabling the development of targeted inhibitors. This led to FDA approvals of sotorasib and adagrasib for KRAS-mutant non-small cell lung cancer, proving the concept was viable. Daraxonrasib represents the next generation of this approach — broader, more potent, and now tested in pancreatic cancer.

At ASCO 2026, trial data published simultaneously in the New England Journal of Medicine showed daraxonrasib roughly doubled survival in pancreatic cancer patients. The announcement prompted a standing ovation from oncologists — an extraordinarily rare response at a major medical conference — signaling that this result is considered a genuine breakthrough by specialists.

For longevity-focused individuals, this matters beyond cancer treatment. KRAS mutations accumulate with age and are implicated in the development of multiple age-related cancers. Drugs that effectively neutralize these mutations could significantly shift the mortality landscape for older adults. Combination trials pairing daraxonrasib with vopimetostat are already underway, suggesting researchers are pursuing even greater efficacy.

Caveats remain: trial populations, duration of benefit, side effect profiles, and real-world applicability need further scrutiny. Phase 3 lung cancer trials are ongoing. Nonetheless, this represents one of the most meaningful advances in oncology in years, with implications stretching well beyond a single cancer type.